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Introduction
The current approved treatments with cholinesterase inhibitors are generally considered as moderately and only symptomatically beneficial for late-stage AD dementia patients 1 . Evidence of potential biological and disease-modifying properties of cholinesterase inhibitors is controversially and critically discussed. No agent tested in randomized clinical trials in Mild Cognitive Impairment (MCI) has met its primary efficacy objectives, measured by clinical rating instruments [2] [3] [4] [5] [6] [7] [8] [9] [10] .
To date, only one study investigating the use of in vivo biomarkers of AD in Donepezil clinical trial has been conducted 11 . On the other hand, further clinical studies on structural imaging markers in MCI subjects have reported conflicting results [12] [13] [14] .
Although cortical-thickness represents a promising structural imaging end point in clinical trials, as it offers a direct assessment of effect sizes expressed in a meaningful metric, [15] [16] [17] no study has investigated the donepezil effect on the cortical mantle yet. This is a post hoc study based on the data collected in the context of the Hippocampus Study Clinical Trial (NCT00403520). The first aim of the trial was to investigate the effect of Donepezil treatment using the hippocampal rate of changes as primary outcome 14 . Here, we are going to consider the impact of donepezil treatment on the thickness rate of change in suspected prodromal AD patients diagnosed using the Free and Cued Selective Reminding Test (FCSRT), a test allowing prognostication of prodromal AD within the group of MCI individuals 18, 19 .
Methods

Study Population
Participants included in the present study were all the patients who performed a baseline and a follow-up MRI scan during the Hippocampus Study Clinical Trial (NCT00403520) 14 . The primary efficacy outcome of the Hippocampus Study was the annualized percentage change (APC) of total hippocampal volume measured by an automated segmentation method. In this post hoc analysis, we explored the effect of Donepezil on the cortical thickness. Each patients received at least 1 dose of doubleblind study medication, and had baseline and follow-up clinical and Magnetic
Resonance Imaging (MRI) assessment.
The details of the patient characteristics have been previously described 14 . Briefly, a total of 332 patients were screened within the national network of Memory Resources and Research Centres (MRRC) consisting of 28 regional university expert centres with neurologists, geriatricians, neuropsychologists, biological and neuroimaging resources in each centre.
Inclusion criteria were: 1) more than 50 years of age; 2) a progressive hippocampal amnestic syndrome defined by Free Recall  17 or Total Recall < 40 on the FCSRT; and 3) no dementia with a CDR stage of 0.5 and preserved cognition and functional performance. Subjects who met the eligibility criteria were enrolled in the randomization phase beginning with Visit 1. From the total population of individuals randomized in the clinical trial (103 Placebo and 113 Donepezil), for the present study we considered exclusively patients who performed MRI at baseline and at the end of the treatment (Placebo=92 and Donepezil= 82).
Study Design
This was a multi-centre double-blind, randomized, placebo-controlled trial with a treatment period of 12 months. The sample power of the study was calculated 
Acquisition of MR images
Brain MRI scans were acquired in each centre at baseline and after at the end of treatment period. All the MRI were performed using 1. 
Cortical Thickness Reconstruction and Surface Analysis
To extract reliable thickness estimates, images were automatically processed with the longitudinal stream 24 in FreeSurfer (http://surfer.nmr.mgh.harvard.edu/) version 5.1. Details on the longitudinal pipeline used to analyzing data are described at the following link (https://surfer.nmr.mgh.harvard.edu/fswiki/LongitudinalProcessing).
Specifically an unbiased within-subject template space and image is created using robust, inverse consistent registration 25 . Several processing steps, such as skull stripping, Talairach transforms, atlas registration as well as spherical surface maps and parcellations are then initialized with common information from the within-subject template, significantly increasing reliability and statistical power 26 . Based on gyral and sulcal anatomy, the cortex was segmented using the Desikan-Killiany Atlas 27 .
For each of cortical regions, mean cortical thickness was calculated as the distance (in mm) between the pial and gray/white matter surfaces. A quality control of data was performed, the Pial and the white matter Surfaces were checked in order to remove any non brain tissue and non-white matter tissue respectively. The cortical thickness was smoothed with 10 mm FWHM Gaussian kernel to improve the signal-to-noise ratio and statistical power.
Statistical Analysis
Demographic, clinical and neuropsychological features were compared between subject groups (Placebo vs Donepezil). Chi-square test was performed on Surface analyses were performed using MATLAB (http://fr.mathworks.com) and the QDEC toolbox of FreeSurfer (www.surfer.nmr.mgh.harvard.edu). One-year changes in bilateral cortical structures were investigated using the Linear Mixed Effects Models. The results were projected onto the template. The surface analyses were rethresholded using a two-stage false discovery rate of 0.05 (FDR2 < 0.05).
Power analysis
Since the original Hippocampus Study trial was not designed for examine cortical thickness, an estimation of samples size needed to detect a thickness change of a certain number of millimetres between placebo and treatment patients was estimated.
Sample size requirements were estimated using the following formula:
, where K = constant, which is a function of α (0.05) and β=0.2 (80%) ; σ is the standard deviation of cortical thickness APC in the untreated group, μ are the mean values of cortical thickness APC in the treatment and placebo groups.
The following modification was included: the sample size thus derived was increased by 10% to allow for losses at follow-up.
Results
From the total sample of 316 individuals (103 Placebo and 113 Donepzil) randomized in the trial, 174 individuals (92 Placebo and 82 Donepezil) underwent both baseline and follow-up MRI scans. One subject of them was excluded from analysis due to a corrupted scan.
No significant differences were found at baseline sociodemographic as well as in cognitive features between groups ( Table 1 ). The Apolipoprotein E (APOE) genotype was present in 18 (47.3%) patients in the placebo group and 18 (60%) in the donepezil showing no substantial differences (p = 0.215) between the two groups.
The baseline cortical thickness, for all brain regions considered, did not show any significant statistical differences between the two groups ( Table 2) .
As detailed in the Figure 1 Recently, our group confirmed the data by Schuff and colleagues 32 for ventricular and whole brain volumes. In addition, we observed a significant reduction in the annual rate of hippocampal atrophy in suspected prodromal AD patients treated with donepezil 33 .
Regional cortical thickness reduction is used as a predictive indicator of AD-related neurodegeneration in MCI subjects 30, 34 . Our results revealed unilateral treatment differences in several brain regions that might be due to normal variation and specialization of function and structure. Brain asymmetry is believed to be evolutionally adaptive, reducing possible interference between hemispheres 35 .
Based on the hypothesis that donepezil may attenuate amyloid-induced neuronal toxicity 36, 37 , it is conceivable that 12 months of donepezil treatment might have a neuroprotective effect on the cortex. In vitro studies demonstrated that lesions of the cholinergic nucleus basalis of Meynert promote the ex vivo synthesis of Aβ precursor protein (AβPP) in the cerebral cortex 38 . Recently, an in vivo neuroimaging study described a correlation between basal forebrain atrophy and elevated cortical amyloid load in preclinical and pre-dementia stages of AD 39 , thus reflecting the association found in several human autopsy studies between amyloid pathology and cholinergic atrophy in AD 40, 41, 42 . Cortical amyloid accumulation might induce cholinergic cell death involving alterations in the levels of intracellular calcium and/or production of toxic and inflammatory mediators such as nitric oxide, cytokines, and reactive oxygen intermediates 43 . On the other hand, a cholinergic stimulation alters positively the mechanisms of amyloid processing, thus protecting neurons from neurodegeneration induced by Aβ 36 .
In this study, we found a trend toward a statistical significance for cortical thinning reduction in the cortical areas innervated by the medial and lateral cholinergic pathways 44 in suspected prodromal AD patients receiving one year of donepezil treatment.
One of the main strengths of the present study is the refined target population deriving from a large-scale community-based multi-centre cohort of subjects included on the basis of the FCSRT, a memory test reported to be highly correlated with hippocampal volume and CSF levels changes of the Alzheimer type 18, 19 .
The study presents potential limitations. First of all, the data used in the present research were not specifically powered for the aims of the present study, thus reducing the significance of the results. The protocol of the study did not include information on the settings of the subjects of the population or on race and ethnicity characteristics or data in terms of lifestyle. The latter, in particular, given its practical aspects -nutrition, hydration, and physical activity -has become significant in terms of AD prevention. We did not collect sufficient data on APOE ε4 genotype to exclude the hypothesis that our results were not significantly impacted by the presence of APOE ε4 genotype. Finally, the subjects have not been followed for a long enough period of time in order to determine the incidence of incipient AD in each group.
Overall, our findings support the hypothesis that cortical thickness might be used as 
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